Interview with Robert Dahan, President, AstraZeneca France
You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry as well as a…
Address: 1 Place Louis Renault, Rueil-Malmaison cedex 92844,France
Tel: 33 (0)1 41 29 40 00
Web: http://www.astrazeneca.fr/accueil/
AstraZeneca provides medical professionals and patients know how and drugs already widely recognized. The French subsidiary of AstraZeneca was the first European subsidiary of the group and the third in the world after the United States and Japan.
With a turnover of 1.23 billion euros in 2008, AstraZeneca is the 6th largest pharmaceutical company in France while employing 1,900 people.
In France, AstraZeneca is involved in all stages of the life of the drug research, development, production, marketing. Besides the headquarters in Rueil-Malmaison and medical networks present throughout the territory, the company has a center of Cancer Research in Reims and two industrial sites in Dunkirk and Reims.
AstraZeneca has a broad range of effective drugs and innovative, designed to combat disease in areas where medical needs are greatest.
ANESTHESIA
HEART
GASTROINTESTINAL ENTEROLOGY
INFECTIOLOGY
ONCOLOGY
RESPIRATORY
CENTRAL NERVOUS SYSTEM
You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry as well as a…
The Chairman & CEO of DBV Technologies reveals how they have developed a new therapeutic method and new technology in the form of a patch to treat various allergies. DBV received…
The President of Cristers discusses the history of generic drugs in France and what steps can be taken to increase generics penetration, while also outlining the ‘cooperative’ business model behind…
Yves Bur reveals how the motivation behind his political engagement has been to raise awareness around the importance of improving the social security system. Bur also explains why having a…
The General Manager of LEEM talks about the association’s strategy based on three key points, innovation, attractiveness and efficiency; how the Mediator affair has placed a question mark on the…
CPhI Worldwide 2014, held this year in Paris, was the largest ever event held by the organizers, with more than 36,000 attendees and 2,500 exhibitors. PharmaBoardroom was a media partner…
Nycomed lost an important patent with Pantoprazole in the middle of 2009, which has undoubtedly warranted some restructuring. What has been the impact of this loss on business in France,…
BMS recently announced divesting from their facilities in Epernon and Meymac but at the same time reinforcing manufacturing in Agen. Could you speak to strategy of this restructuring within France…
You worked for many years in emerging markets, especially in Latin America, but also in neighbor countries such as Spain. How these previous experiences in very different markets can now…
In the wake of the most recent CSIS meeting, LFB and Sanofi-Aventis announced the intention to collaborate in bioproduction. What are the terms to this agreement and what are the…
We have had the chance to interview a number of Teva’s subsidiaries in Europe, and witnessed how each of them has dealt with the strong transformations that the group has…
Historically, UCB Pharma had a much more ‘traditional’ approach to the industry with a broader scope of operations. Recently, the company reoriented in the direction of biopharmaceuticals by moving away…
Novo Nordisk just celebrated 50 years in France; what have been some of the more recent events that have marked the affiliate’s time here? If you look from the perspective…
See our Cookie Privacy Policy Here
